An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care
- Author
- Velislava Zoteva (UGent) , Valerie De Meulenaere (UGent) , Marthe De Boeck, Christian Vanhove (UGent) , Luc Leybaert (UGent) , Robrecht Raedt (UGent) , Leen Pieters (UGent) , Anne Vral (UGent) , Tom Boterberg (UGent) and Karel Deblaere (UGent)
- Organization
- Abstract
- Glioblastoma (GB) is the most common and malignant primary brain tumor in adults with a median survival of 12–15 months. The F98 Fischer rat model is one of the most frequently used animal models for GB studies. However, suboptimal inoculation leads to extra-axial and extracranial tumor formations, affecting its translational value. We aim to improve the F98 rat model by incorporating MRI-guided (hypo)fractionated radiotherapy (3 x 9 Gy) and concomitant temozolomide chemotherapy, mimicking the current standard of care. To minimize undesired tumor growth, we reduced the number of inoculated cells (starting from 20 000 to 500 F98 cells), slowed the withdrawal of the syringe post-inoculation, and irradiated the inoculation track separately. Our results reveal that reducing the number of F98 GB cells correlates with a diminished risk of extra-axial and extracranial tumor growth. However, this introduces higher variability in days until GB confirmation and uniformity in GB growth. To strike a balance, the model inoculated with 5000 F98 cells displayed the best results and was chosen as the most favorable. In conclusion, our improved model offers enhanced translational potential, paving the way for more accurate and reliable assessments of novel adjuvant therapeutic approaches for GB.
- Keywords
- Multidisciplinary
Downloads
-
journal.pone.0296360.pdf
- full text (Published version)
- |
- open access
- |
- |
- 1.96 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HKS8S4ZX50NERX9HNN8RE73X
- MLA
- Zoteva, Velislava, et al. “An Improved F98 Glioblastoma Rat Model to Evaluate Novel Treatment Strategies Incorporating the Standard of Care.” PLOS ONE, edited by Michael C Burger, vol. 19, no. 1, Public Library of Science (PLoS), 2024, doi:10.1371/journal.pone.0296360.
- APA
- Zoteva, V., De Meulenaere, V., De Boeck, M., Vanhove, C., Leybaert, L., Raedt, R., … Deblaere, K. (2024). An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care. PLOS ONE, 19(1). https://doi.org/10.1371/journal.pone.0296360
- Chicago author-date
- Zoteva, Velislava, Valerie De Meulenaere, Marthe De Boeck, Christian Vanhove, Luc Leybaert, Robrecht Raedt, Leen Pieters, Anne Vral, Tom Boterberg, and Karel Deblaere. 2024. “An Improved F98 Glioblastoma Rat Model to Evaluate Novel Treatment Strategies Incorporating the Standard of Care.” Edited by Michael C Burger. PLOS ONE 19 (1). https://doi.org/10.1371/journal.pone.0296360.
- Chicago author-date (all authors)
- Zoteva, Velislava, Valerie De Meulenaere, Marthe De Boeck, Christian Vanhove, Luc Leybaert, Robrecht Raedt, Leen Pieters, Anne Vral, Tom Boterberg, and Karel Deblaere. 2024. “An Improved F98 Glioblastoma Rat Model to Evaluate Novel Treatment Strategies Incorporating the Standard of Care.” Ed by. Michael C Burger. PLOS ONE 19 (1). doi:10.1371/journal.pone.0296360.
- Vancouver
- 1.Zoteva V, De Meulenaere V, De Boeck M, Vanhove C, Leybaert L, Raedt R, et al. An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care. Burger MC, editor. PLOS ONE. 2024;19(1).
- IEEE
- [1]V. Zoteva et al., “An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care,” PLOS ONE, vol. 19, no. 1, 2024.
@article{01HKS8S4ZX50NERX9HNN8RE73X,
abstract = {{Glioblastoma (GB) is the most common and malignant primary brain tumor in adults with a median survival of 12–15 months. The F98 Fischer rat model is one of the most frequently used animal models for GB studies. However, suboptimal inoculation leads to extra-axial and extracranial tumor formations, affecting its translational value. We aim to improve the F98 rat model by incorporating MRI-guided (hypo)fractionated radiotherapy (3 x 9 Gy) and concomitant temozolomide chemotherapy, mimicking the current standard of care. To minimize undesired tumor growth, we reduced the number of inoculated cells (starting from 20 000 to 500 F98 cells), slowed the withdrawal of the syringe post-inoculation, and irradiated the inoculation track separately. Our results reveal that reducing the number of F98 GB cells correlates with a diminished risk of extra-axial and extracranial tumor growth. However, this introduces higher variability in days until GB confirmation and uniformity in GB growth. To strike a balance, the model inoculated with 5000 F98 cells displayed the best results and was chosen as the most favorable. In conclusion, our improved model offers enhanced translational potential, paving the way for more accurate and reliable assessments of novel adjuvant therapeutic approaches for GB.}},
articleno = {{e0296360}},
author = {{Zoteva, Velislava and De Meulenaere, Valerie and De Boeck, Marthe and Vanhove, Christian and Leybaert, Luc and Raedt, Robrecht and Pieters, Leen and Vral, Anne and Boterberg, Tom and Deblaere, Karel}},
editor = {{Burger, Michael C}},
issn = {{1932-6203}},
journal = {{PLOS ONE}},
keywords = {{Multidisciplinary}},
language = {{eng}},
number = {{1}},
pages = {{18}},
publisher = {{Public Library of Science (PLoS)}},
title = {{An improved F98 glioblastoma rat model to evaluate novel treatment strategies incorporating the standard of care}},
url = {{http://doi.org/10.1371/journal.pone.0296360}},
volume = {{19}},
year = {{2024}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: